News from stealth biotherapeutics inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 12, 2022, 07:30 ET Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

May 02, 2022, 07:30 ET STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY

Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

Apr 11, 2022, 08:30 ET Stealth BioTherapeutics Announces $8.5 Million in Equity Financings

Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company"), a clinical-stage biotechnology company focused on the discovery, development and...

Mar 30, 2022, 16:30 ET Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Mar 28, 2022, 07:30 ET Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's Ataxia

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Mar 24, 2022, 07:30 ET Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022)

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Mar 17, 2022, 16:30 ET Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in Dry Age-Related Macular Degeneration

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Mar 16, 2022, 16:30 ET Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Association and Clinical Scientific Conference

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Mar 09, 2022, 17:00 ET Stealth BioTherapeutics to Present at Upcoming March Investor Conferences

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Feb 22, 2022, 07:30 ET Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Feb 15, 2022, 07:30 ET Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Feb 11, 2022, 17:30 ET Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value Of Publicly Held Shares Requirement

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Feb 08, 2022, 07:30 ET Stealth BioTherapeutics Announces Oral Presentation of New Duchenne Muscular Dystrophy Data at the 2022 Muscular Dystrophy Association Clinical and Scientific Conference

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Jan 07, 2022, 16:30 ET Stealth BioTherapeutics Receives Nasdaq Notifications Regarding Minimum Bid And Market Value Requirements

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Jan 04, 2022, 07:30 ET Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Dec 20, 2021, 07:30 ET Stealth BioTherapeutics Reports Positive Pre-IND Meeting for Duchenne Muscular Dystrophy

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Dec 13, 2021, 07:30 ET Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Nov 11, 2021, 07:30 ET Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Nov 04, 2021, 07:30 ET Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Oct 20, 2021, 07:30 ET Stealth BioTherapeutics Receives Refusal to File Letter from the FDA

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Oct 07, 2021, 17:00 ET Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Oct 04, 2021, 07:30 ET Stealth BioTherapeutics Completes a $25 Million Debt Financing with Horizon Technology Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of...

Sep 28, 2021, 07:30 ET Stealth BioTherapeutics Presents Positive Elamipretide Data in Pediatric Cardiology at International Society for Heart Research North American Section Meeting 2021

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Sep 23, 2021, 07:30 ET Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Sep 07, 2021, 16:30 ET Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...